Price changes, market opportunities
As Pharma Footpath develops its databases, we're able to quickly drill down into the commercial opportunities. Where I think this is most interesting currently is in looking at renegotiated prices in different markets, and taking advantage of these before others do.
Examples of this include:
- 50% reduction in price for Australian Xolair PFS, bringing this below EU market. Valuable for the 54 clinical trials globally, and for the wider number of trading opportunities that come from these English language packs
- The centrally authorised product Pradaxa has had over 300 parallel trade licenses granted, and is listed in 65 clinical trials globally. A recent price reduction of over 20% in Hungary makes this an import area to review
It's clear from the data that when price changes occur, they don't happen in a synchronized fashion. That creates opportunities for finding the markets that have the earliest price movement, but also acts as a warning to companies about committing to purchasing product that may be about to undergo significant market changes (Revlimid is a prime example in Europe!)
If you'd like to talk more about these points, please get in touch! I'm always keen to talk more about the insights we're finding, and what we can build from it to make your business win more.
Phil
